Compare Stocks: RPTX, BNTC, CMPX, and PRTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.31 +1.2%	$12.72	$9.85 ▼ $16.76	$418.09M	0.27	187,784 shs	78,296 shs
CMPX Compass Therapeutics	$2.31 -3.3%	$2.20	$1.61 ▼ $6.88	$430.41M	0.95	3.21 million shs	1.51 million shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-2.41%	-4.25%	+3.93%	+15.03%	-8.08%
CMPX Compass Therapeutics	-0.42%	-0.42%	+25.13%	+14.90%	-31.52%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	+2.05%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+58.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.31 +1.2%	$12.72	$9.85 ▼ $16.76	$418.09M	0.27	187,784 shs	78,296 shs
CMPX Compass Therapeutics	$2.31 -3.3%	$2.20	$1.61 ▼ $6.88	$430.41M	0.95	3.21 million shs	1.51 million shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-2.41%	-4.25%	+3.93%	+15.03%	-8.08%
CMPX Compass Therapeutics	-0.42%	-0.42%	+25.13%	+14.90%	-31.52%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	+2.05%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+58.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	2.60	Moderate Buy	$24.80	101.46% Upside
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	409.49% Upside
PRTC PureTech Health	1.00	Sell	N/A	N/A
RPTX Repare Therapeutics	2.00	Hold	$3.00	13.21% Upside

Current Analyst Ratings Breakdown

Latest RPTX, BNTC, CMPX, and PRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/17/2026	BNTC Benitec Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	CMPX Compass Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
6/10/2026	BNTC Benitec Biopharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/4/2026	CMPX Compass Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
6/1/2026	CMPX Compass Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$6.00

(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$3.71 per share	N/A
CMPX Compass Therapeutics	$850K	489.42	N/A	N/A	$0.92 per share	2.51
PRTC PureTech Health	$4.66M	91.01	N/A	N/A	$12.65 per share	1.38
RPTX Repare Therapeutics	$11.87M	9.62	N/A	N/A	$3.56 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$37.92M	-$1.14	N/A	N/A	N/A	N/A	-34.82%	-34.11%	9/28/2026 (Estimated)
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
PRTC PureTech Health	-$109.74M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	-$84.69M	-$1.69	N/A	N/A	N/A	N/A	-60.15%	-52.24%	N/A

Latest RPTX, BNTC, CMPX, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/28/2026	Q4 2026	BNTC Benitec Biopharma	-$0.26	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	N/A	56.82	56.82
CMPX Compass Therapeutics	N/A	11.22	11.22
PRTC PureTech Health	N/A	6.59	6.59
RPTX Repare Therapeutics	N/A	10.71	10.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
CMPX Compass Therapeutics	68.43%
PRTC PureTech Health	0.04%
RPTX Repare Therapeutics	85.09%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	4.80%
CMPX Compass Therapeutics	18.70%
PRTC PureTech Health	5.30%
RPTX Repare Therapeutics	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	34.35 million	32.71 million	No Data
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
PRTC PureTech Health	100	24.34 million	23.05 million	Not Optionable
RPTX Repare Therapeutics	180	43.11 million	38.15 million	Optionable

RPTX, BNTC, CMPX, and PRTC Headlines

Recent News About These Companies

Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million

July 27, 2026 | theglobeandmail.com

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

January 16, 2026 | financialpost.comF

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

January 16, 2026 | businesswire.com

Repare Therapeutics announces Gilead to acquire RP-3467 for up to $30M

December 25, 2025 | msn.com

Why Repare Therapeutics Inc.’s (RPTX) Stock Is Up 19.82%

December 25, 2025 | aaii.comA

RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug

December 24, 2025 | msn.com

Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug

December 24, 2025 | ca.investing.com

Gilead to buy Repare Thera’s cancer candidate for up to $30M

December 24, 2025 | msn.com

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

December 24, 2025 | businesswire.com

Halper Sadeh LLC Encourages RPTX, THS, RMBI Shareholders to Contact the Firm to Discuss Their Rights

November 27, 2025 | caledonianrecord.comC

Repare shareholders vote in favor of Xeno bid

November 22, 2025 | thepharmaletter.comT

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

November 20, 2025 | financialpost.comF

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

November 20, 2025 | businesswire.com

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

November 18, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)

November 17, 2025 | globenewswire.com

Repare Therapeutics downgraded to Hold from Buy at TD Cowen

November 17, 2025 | msn.com

Repare Therapeutics stock soars after acquisition deal with XenoTherapeutics

November 14, 2025 | za.investing.com

XenoTherapeutics to acquire Repare Therapeutics for $1.82 p/s plus one CVR

November 14, 2025 | msn.com

Repare Therapeutics enters into definitive agreement to be acquired by xenotherapeutics

November 14, 2025 | msn.com

RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders

November 14, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, BNTC, CMPX, and PRTC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$12.31 +0.14 (+1.15%)

As of 04:00 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Compass Therapeutics NASDAQ:CMPX

$2.31 -0.08 (-3.35%)

As of 04:00 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)

As of 08/31/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Repare Therapeutics NASDAQ:RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, BNTC, CMPX, and PRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, BNTC, CMPX, and PRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, BNTC, CMPX, and PRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, BNTC, CMPX, and PRTC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Compass Therapeutics NASDAQ:CMPX

PureTech Health NASDAQ:PRTC

Repare Therapeutics NASDAQ:RPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, BNTC, CMPX, and PRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, BNTC, CMPX, and PRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, BNTC, CMPX, and PRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, BNTC, CMPX, and PRTC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Compass Therapeutics NASDAQ:CMPX

PureTech Health NASDAQ:PRTC

Repare Therapeutics NASDAQ:RPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools